Retrospective analysis shows adverse survival outcomes in adults with acute megakaryoblastic leukemia, highlighting the role of TP53 mutations and allo-HSCT.
Key Points
Overall survival was significantly improved with allo-HSCT, demonstrating a notable survival difference of 70 weeks versus 17 weeks for chemotherapy alone.
Rates of complete remission following treatment were low, with only 30% in first-line and 20% in salvage therapy settings among patients with acute megakaryoblastic leukemia.
Cytogenetic abnormalities were prevalent, with complex karyotypes found in over half of the cases, indicating a severe prognosis based on standard classification.
Elevated levels of LDH and presence of antecedent hematologic disorders were identified as predictors of inferior overall survival outcomes.